Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 38 entries
View as:

Masitinib in Patients With Symptomatic Mild to Moderate COVID-19

Phase: N/A Priority: Normal
NCT ID: NCT05047783 Org: User:
Start: 11/23/21 End: 12/31/23 Due: 12/31/24

Masitinib in Patients With Gastrointestinal Stromal Tumour After Progression With Imatinib

Phase: N/A Priority: Normal
NCT ID: NCT01694277 Org: User:
Start: 04/30/12 End: 12/31/20 Due: 12/31/21

Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis

Phase: N/A Priority: Normal
NCT ID: NCT00814073 Org: User:
Start: 12/31/08 End: 11/30/15 Due: 11/30/16

Masitinib in Combination With FOLFIRI in Third or Fourth Line of Treatment of Patients With Metastatic Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03556956 Org: User:
Start: 07/31/15 End: 12/31/20 Due: 12/31/21

Efficacy of Oral AB1010 in Adult Patients With Active Rheumatoid Arthritis

Phase: N/A Priority: Normal
NCT ID: NCT00831922 Org: User:
Start: 09/30/04 End: - Due: -

Masitinib Plus Docetaxel in Metastatic Castration-resistant Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03761225 Org: User:
Start: 09/30/14 End: 12/15/20 Due: 12/15/21

Masitinib in First Line Treatment of Gastro-Intestinal Stromal Tumor (GIST)

Phase: N/A Priority: Normal
NCT ID: NCT00812240 Org: User:
Start: 01/31/09 End: 07/31/18 Due: 07/31/19

Masitinib in Treatment of Patients With Severe Persistent Asthma Treated With Oral Corticosteroids

Phase: N/A Priority: Normal
NCT ID: NCT01449162 Org: User:
Start: 01/31/11 End: 11/30/19 Due: 11/30/20

Masitinib in Combination With Gemcitabine for Treatment of Patients With Advanced/Metastatic Pancreatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00789633 Org: User:
Start: 11/25/08 End: 08/31/12 Due: 08/31/13

Masitinib in Patients With Mild to Moderate Alzheimer's Disease

Phase: N/A Priority: Normal
NCT ID: NCT05564169 Org: User:
Start: 01/31/24 End: 12/31/26 Due: 12/31/27

Masitinib in Relapse or Refractory Multiple Myeloma With t(4/14) Translocation Expressing or Not FGFR3

Phase: N/A Priority: Normal
NCT ID: NCT00866138 Org: User:
Start: 02/28/05 End: 01/31/11 Due: 01/31/12

Masitinib in Combination With Gemcitabine in Advanced/Metastatic Epithelial Ovarian Cancer Patients

Phase: N/A Priority: Normal
NCT ID: NCT02490488 Org: User:
Start: 04/30/14 End: 12/31/20 Due: 12/31/21

Efficacy of Oral AB1010 in Adult Patients With Severe Persistent Corticosteroid Dependent Asthma

Phase: N/A Priority: Normal
NCT ID: NCT00842270 Org: User:
Start: 01/31/06 End: - Due: -

Masitinib in Patients With Localized, Primary GIST After Complete Surgery and With High Risk of Recurrence

Phase: N/A Priority: Normal
NCT ID: NCT02009423 Org: User:
Start: 07/31/15 End: 11/30/15 Due: 11/30/16

Masitinib in Combination With Riluzole for the Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS)

Phase: N/A Priority: Normal
NCT ID: NCT02588677 Org: User:
Start: 04/30/13 End: 03/31/18 Due: 03/31/19

Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients

Phase: N/A Priority: Normal
NCT ID: NCT03127267 Org: User:
Start: 02/02/21 End: 12/31/23 Due: 12/31/24

Activity of Masitinib (AB1010) in Mild to Moderate Alzheimer's Disease

Phase: N/A Priority: Normal
NCT ID: NCT00976118 Org: User:
Start: 02/28/06 End: 02/28/09 Due: 02/28/10

Masitinib in Combination With Methotrexate, in Treatment of Patients With Active Rheumatoid Arthritis

Phase: N/A Priority: Normal
NCT ID: NCT00913432 Org: User:
Start: 03/31/07 End: 09/30/10 Due: 09/30/11

Efficacy and Safety of Masitinib in the Treatment of Progressive Multiple Sclerosis

Phase: N/A Priority: Normal
NCT ID: NCT01433497 Org: User:
Start: 08/31/11 End: 02/29/20 Due: 02/28/21

Masitinib in Primary Progressive Multiple Sclerosis or Relapse-free Secondary Progressive Multiple Sclerosis

Phase: N/A Priority: Normal
NCT ID: NCT01450488 Org: User:
Start: 06/30/05 End: 01/31/10 Due: 01/31/11

Masitinib for the Treatment of Severe Mast Cell Activation Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT05449444 Org: User:
Start: 07/01/22 End: 12/31/24 Due: 12/31/25

A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT01470131 Org: User:
Start: 05/31/11 End: 02/01/17 Due: 02/01/18

Masitinib in Patients With Mild to Moderate Alzheimer's Disease

Phase: N/A Priority: Normal
NCT ID: NCT01872598 Org: User:
Start: 01/31/12 End: 12/31/20 Due: 12/31/21

Masitinib in the Treatment of Patients With Severe Uncontrolled Asthma and Elevated Eosinophil Levels

Phase: N/A Priority: Normal
NCT ID: NCT03771040 Org: User:
Start: 12/31/16 End: 09/30/20 Due: 09/30/21

A Double-blind, Placebo-controlled, Randomized, Parallel-group Study to Evaluate the Activity of Oral AB1010 in Adults Patients With Moderate to Severe Chronic Plaque Psoriasis

Phase: N/A Priority: Normal
NCT ID: NCT01045577 Org: User:
Start: 09/30/05 End: 02/29/08 Due: 02/28/09